CY1105536T1 - Η ΑΝΟΣΟΣΦΑΙΡΙΝΗ IgG3 ΣΑΝ ΔΕΙΚΤΗΣ ΠΡΟΣΤΑΣΙΑΣ ΕΝΑΝΤΙΑ ΣΤΙΣ ΜΟΛΥΣΜΑΤΙΚΕΣ ΙΪΚΕΣ ΑΣΘΕΝΕΙΕΣ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΗΣ - Google Patents

Η ΑΝΟΣΟΣΦΑΙΡΙΝΗ IgG3 ΣΑΝ ΔΕΙΚΤΗΣ ΠΡΟΣΤΑΣΙΑΣ ΕΝΑΝΤΙΑ ΣΤΙΣ ΜΟΛΥΣΜΑΤΙΚΕΣ ΙΪΚΕΣ ΑΣΘΕΝΕΙΕΣ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΗΣ

Info

Publication number
CY1105536T1
CY1105536T1 CY20061101270T CY061101270T CY1105536T1 CY 1105536 T1 CY1105536 T1 CY 1105536T1 CY 20061101270 T CY20061101270 T CY 20061101270T CY 061101270 T CY061101270 T CY 061101270T CY 1105536 T1 CY1105536 T1 CY 1105536T1
Authority
CY
Cyprus
Prior art keywords
igg3
viral diseases
infectious viral
immunospherein
indicator
Prior art date
Application number
CY20061101270T
Other languages
English (en)
Inventor
Jean-Claude Chermann
Camille Haslin
Ricardo De Oliveira
Original Assignee
Urrma R & D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urrma R & D filed Critical Urrma R & D
Publication of CY1105536T1 publication Critical patent/CY1105536T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αφορά μιας νέα απομονωμένη και/ή καθαρισμένη παραλλαγή της ανοσοσφαιρίνης IgG3 που είναι χρήσιμη σαν δείκτης προστασίας για μολυσματικές ιϊκές ασθένειες όπως το AIDS, και σαν διαγνωστικό εργαλείο ή σαν προληπτικό και θεραπευτικό φάρμακο. Αξιώνονται οι αντίστοιχες in vitro διαγνωστικές μέθοδοι.
CY20061101270T 2002-02-15 2006-09-06 Η ΑΝΟΣΟΣΦΑΙΡΙΝΗ IgG3 ΣΑΝ ΔΕΙΚΤΗΣ ΠΡΟΣΤΑΣΙΑΣ ΕΝΑΝΤΙΑ ΣΤΙΣ ΜΟΛΥΣΜΑΤΙΚΕΣ ΙΪΚΕΣ ΑΣΘΕΝΕΙΕΣ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΗΣ CY1105536T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0201960A FR2836146B1 (fr) 2002-02-15 2002-02-15 IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
PCT/FR2003/000463 WO2003068820A1 (fr) 2002-02-15 2003-02-13 IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS

Publications (1)

Publication Number Publication Date
CY1105536T1 true CY1105536T1 (el) 2010-07-28

Family

ID=27636232

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101270T CY1105536T1 (el) 2002-02-15 2006-09-06 Η ΑΝΟΣΟΣΦΑΙΡΙΝΗ IgG3 ΣΑΝ ΔΕΙΚΤΗΣ ΠΡΟΣΤΑΣΙΑΣ ΕΝΑΝΤΙΑ ΣΤΙΣ ΜΟΛΥΣΜΑΤΙΚΕΣ ΙΪΚΕΣ ΑΣΘΕΝΕΙΕΣ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΗΣ

Country Status (11)

Country Link
US (2) US7306798B2 (el)
EP (1) EP1476467B9 (el)
AT (1) ATE328905T1 (el)
AU (1) AU2003226884A1 (el)
CY (1) CY1105536T1 (el)
DE (1) DE60305884T2 (el)
DK (1) DK1476467T3 (el)
ES (1) ES2266832T3 (el)
FR (1) FR2836146B1 (el)
PT (1) PT1476467E (el)
WO (1) WO2003068820A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021800A1 (en) * 1995-06-30 2003-01-30 Jean-Claude Chermann Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis
EP2094733A1 (en) * 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
TW200846363A (en) * 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646607B1 (fr) 1989-05-03 1991-08-30 Inst Nat Sante Rech Med Anticorps monoclonaux anti-b2 microglobuline
GB8916400D0 (en) * 1989-07-18 1989-09-06 Dynal As Modified igg3
US20030021800A1 (en) * 1995-06-30 2003-01-30 Jean-Claude Chermann Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic

Also Published As

Publication number Publication date
US7306798B2 (en) 2007-12-11
DK1476467T3 (da) 2006-10-16
EP1476467A1 (fr) 2004-11-17
WO2003068820A9 (fr) 2004-05-27
ES2266832T3 (es) 2007-03-01
US20080286755A1 (en) 2008-11-20
AU2003226884A1 (en) 2003-09-04
PT1476467E (pt) 2006-10-31
FR2836146B1 (fr) 2005-01-07
DE60305884D1 (de) 2006-07-20
DE60305884T2 (de) 2007-03-01
EP1476467B9 (fr) 2007-01-03
WO2003068820A1 (fr) 2003-08-21
EP1476467B1 (fr) 2006-06-07
FR2836146A1 (fr) 2003-08-22
ATE328905T1 (de) 2006-06-15
US20050152910A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
CY1105536T1 (el) Η ΑΝΟΣΟΣΦΑΙΡΙΝΗ IgG3 ΣΑΝ ΔΕΙΚΤΗΣ ΠΡΟΣΤΑΣΙΑΣ ΕΝΑΝΤΙΑ ΣΤΙΣ ΜΟΛΥΣΜΑΤΙΚΕΣ ΙΪΚΕΣ ΑΣΘΕΝΕΙΕΣ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΗΣ
BRPI0411582A (pt) substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
CY1108041T1 (el) Αναστολεις της rho-κινασης
CY1108578T1 (el) Φαρμακευτικες συνθεσεις (κιτ) περιλαμβανοντας ενωσεις διϋδροπυριδινονης και εναν ανοσορυθμιστικο (ή εναν αντιφλεγμονωδη) παραγοντα και οι χρησεις αυτων
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
BRPI0818672B8 (pt) composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas
CY1113413T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
CY1107871T1 (el) Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2
CY1108894T1 (el) Νεα παραγωγα βενζιμιδαζολης
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
PA8547701A1 (es) Nucleosidos 4 substituidos.
BRPI0414799A (pt) bifenilóxi-ácidos
ATE408601T1 (de) Fredericamycin-derivate
BRPI0413742A (pt) derivados de mitoquinona usados como antioxidantes mitocondrialmente alvejados
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
UY28313A1 (es) Nonadepsipeptidos acilados
TR200200310T2 (tr) Interlökin-5 inhibe eden 6-azaurasil türevleri.
BR0312863A (pt) Derivados de aldeìdo de polietileno glicol
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene